Multiple sclerosis presents persistent diagnostic dilemmas for physicians worldwide because its initial clinical presentations closely mimic various central nervous system disorders. Consequently, clinicians often struggle to establish definitive early diagnoses based entirely on initial neuroimaging and physical examinations. Detecting demyelinating pathology during initial stages remains paramount to prevent permanent axonal transection and severe functional disability. Fortunately, recent genomic investigations highlight circulating long noncoding RNAs as revolutionary diagnostic instruments. Identifying a reliable multiple sclerosis biomarker in peripheral blood can fundamentally transform standard clinical pathways. A seminal molecular study examined the differential expression profiles of long noncoding RNAs in peripheral blood cells across diverse disease subtypes. The investigators analyzed blood samples from one hundred healthy control participants alongside one hundred twenty affected patients. They specifically studied patients with relapsing-remitting, primary progressive, and secondary progressive forms. Through quantitative real-time polymerase chain reaction and receiver operating characteristic analyses, the investigators demonstrated substantial transcriptional alterations. Their findings provide compelling molecular insights into neuroinflammation.

The Emerging Role of Noncoding RNAs in Demyelinating Disease

Long noncoding RNAs represent functional RNA transcripts exceeding two hundred nucleotides that modulate gene transcription without coding for functional proteins. Consequently, these epigenetic regulators orchestrate essential immunological mechanisms, including lymphocyte differentiation, cytokine synthesis, and central neuroinflammation. In neurodegenerative pathology, aberrant noncoding transcript networks disrupt normal immunological tolerance and accelerate destructive inflammatory cascades. Previously, investigators struggled to obtain reliable neural tissue biopsies to track these delicate molecular cascades. Peripheral blood mononuclear cells, however, mirror systemic immunological shifts and central nervous system disturbances with remarkable fidelity. Therefore, circulating noncoding transcripts serve as accessible liquid biopsy candidates for tracking dynamic disease mechanisms. Dysregulation of noncoding transcripts alters microRNA sponging and chromatin remodeling within circulating T cells and monocytes. When these peripheral immune cells migrate across the disrupted blood-brain barrier, they perpetuate targeted myelin sheath destruction. In addition, altered transcriptional networks disturb normal remyelination and hasten neuroaxonal degeneration over time. By evaluating these epigenetic markers in peripheral leukocytes, clinicians gain valuable access into real-time immune dysregulation. This molecular understanding bridges the historical gap between peripheral immunopathology and progressive central nervous system damage.

Downregulation of IFNG-AS1 and UCHL1-AS1 in Peripheral Blood

The research evaluated two distinct long noncoding transcripts, specifically IFNG-AS1 and UCHL1-AS1, in peripheral blood cells. Quantitative real-time polymerase chain reaction demonstrated that both noncoding transcripts exhibited profound downregulation in affected cohorts compared to healthy controls. Specifically, IFNG-AS1 functions as an antisense transcript neighboring the interferon-gamma gene, a central master regulator of Th1 cellular immunity. Normally, this antisense RNA coordinates interferon-gamma transcription, ensuring controlled immune responses against infectious challenges. However, significant depletion of IFNG-AS1 destabilizes typical immune regulatory checkpoints, thereby permitting unrestricted proinflammatory signaling cascades. Similarly, UCHL1-AS1 acts as an antisense regulator for ubiquitin carboxy-terminal hydrolase L1, an enzyme critical for proteasomal protein degradation. Within healthy neurons and immune cells, proper proteasomal clearance prevents cytotoxic protein aggregation and cellular apoptosis. Consequently, decreased UCHL1-AS1 expression impairs neuronal proteostasis and perturbs normal immune cell survival. When researchers compared transcriptional profiles, both transcripts exhibited significantly reduced copy numbers across the patient cohort. These molecular depressions highlight substantial systemic dysfunction in leukocyte gene control. Thus, the simultaneous downregulation of these two regulatory transcripts highlights profound immune dysregulation in patient circulation.

Clinical Utility of IFNG-AS1 as a Multiple Sclerosis Biomarker

To determine diagnostic capability, the investigators utilized receiver operating characteristic curve analysis for each individual transcript. Consequently, the statistical evaluation positioned IFNG-AS1 as a particularly potent multiple sclerosis biomarker candidate with high diagnostic accuracy. The receiver operating characteristic analysis yielded an impressive area under the curve, confirming robust sensitivity and specificity. Therefore, measuring circulating levels of IFNG-AS1 reliably discriminates affected individuals from healthy controls in clinical cohorts. In contrast, conventional diagnostic approaches rely heavily on brain magnetic resonance imaging and invasive lumbar punctures. While cerebrospinal fluid oligoclonal bands provide substantial confirmatory value, obtaining spinal fluid carries patient discomfort and procedural risks. A peripheral blood assay offers a minimally invasive alternative that clinicians can repeat readily over longitudinal follow-up. Moreover, peripheral quantification requires standard quantitative real-time PCR infrastructure, which remains widely available across diagnostic laboratories. Tracking transcriptional alterations may also help neurologists assess immediate disease activity during active clinical relapses. Thus, implementing IFNG-AS1 quantification into standard initial workups could expedite clinical decision-making and reduce diagnostic latency. Ultimately, this molecular biomarker provides an objective laboratory tool to substantiate clinical and radiological impressions.

Differentiating Multiple Sclerosis Phenotypes and Neuroinflammation

The investigative cohort incorporated ninety-eight relapsing-remitting patients, ten primary progressive cases, and twelve secondary progressive individuals. Therefore, the researchers evaluated whether noncoding RNA expression differed significantly across distinct clinical trajectories and disease phases. Interestingly, relapsing-remitting patients exhibited pronounced transcriptional alterations, reflecting the intense peripheral immune cell activation characteristic of acute inflammatory flares. In contrast, progressive phenotypes demonstrated persistent transcriptional suppression, suggesting long-standing epigenetic reprogramming during chronic neurodegenerative stages. Consequently, distinguishing these distinct transcriptional profiles could assist clinicians in stratifying patient cohorts more accurately during baseline evaluations. Currently, clinicians face significant hurdles when attempting to predict whether relapsing disease will convert into secondary progression. Furthermore, monitoring peripheral biomarkers may clarify the precise biological transition from acute inflammatory demyelination to chronic compartmentalized neurodegeneration. When combined with conventional disability scoring, longitudinal transcript analysis provides quantitative metrics of biological disease burden. Clinicians can potentially track how novel disease-modifying therapies restore circulating transcript levels back toward healthy baselines. Therefore, profiling these long noncoding RNAs refines our comprehension of phenotypic heterogeneity across diverse patient populations.

Diagnostic Implications for Neurologists and Indian Clinical Practice

In India, diagnosing multiple sclerosis demands careful clinical acumen because several mimicking disorders show high regional prevalence. Specifically, Indian neurologists frequently encounter neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Furthermore, central nervous system tuberculosis, neurosarcoidosis, and infectious demyelination regularly confound initial clinical presentations. Misdiagnosing an atypical presentation can lead to inappropriate immunomodulatory treatments that exacerbate underlying autoimmune conditions. Consequently, integrating noncoding RNA biomarkers into secondary and tertiary medical centers offers crucial diagnostic clarity. Routine diagnostic centers across Indian metropolitan hubs already possess the thermal cyclers and molecular platforms necessary for quantitative PCR. Therefore, validating IFNG-AS1 in diverse regional cohorts could facilitate rapid, cost-effective blood testing alongside magnetic resonance imaging. Moreover, primary care physicians and general internists can utilize objective peripheral assays to prompt timely neurological referrals. Early diagnostic confirmation enables immediate initiation of disease-modifying therapies, which preserves long-term functional independence and cognitive reserve. As healthcare infrastructure continues to modernize across India, peripheral genetic biomarkers represent scalable tools for precision neurology. Consequently, embracing these genomic advances will enhance clinical decision-making and improve long-term outcomes for patients nationwide.

How does IFNG-AS1 function in the pathogenesis of multiple sclerosis?

IFNG-AS1 serves as a long noncoding antisense RNA that directly controls the transcription of interferon-gamma. Interferon-gamma acts as a potent master driver of Th1-mediated autoimmune inflammation within the central nervous system. When IFNG-AS1 experiences significant downregulation, immune cells lose normal transcriptional inhibition over proinflammatory cascades. Consequently, unrestrained cytokine release accelerates peripheral leukocyte autoreactivity, facilitates blood-brain barrier disruption, and promotes inflammatory demyelination across vulnerable cerebral and spinal axonal tracts.

Can peripheral blood lncRNAs replace MRI in clinical multiple sclerosis diagnosis?

Peripheral blood noncoding RNAs cannot completely replace magnetic resonance imaging in contemporary neurology practice. Neuroimaging remains indispensable for visualizing spatial dissemination, active gadolinium enhancement, and chronic neuroaxonal tissue loss. However, quantifying circulating transcripts like IFNG-AS1 offers a minimally invasive, highly complementary molecular instrument. This peripheral assay assists clinicians when neuroimaging results appear equivocal. Furthermore, it expedites timely specialty referrals and enables longitudinal disease tracking without requiring repeated invasive lumbar punctures or contrast administrations.

Why is differential diagnosis especially challenging in Indian patients with suspected demyelination?

Differential diagnosis in Indian clinical settings presents unique complexities due to overlapping neuroinflammatory conditions. Specifically, Indian clinicians encounter high frequencies of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody diseases. Additionally, central nervous system infections, such as tuberculosis, frequently produce confounding radiological features. Misdiagnosing these mimicking conditions can result in harmful therapeutic choices. Therefore, integrating objective molecular biomarkers ensures accurate disease identification and promotes prompt, tailored immunomodulatory intervention.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Rajabi A et al. Downregulation of IFNG-AS1 and UCHL1-AS1 in Peripheral Blood Cells of Multiple Sclerosis Patients: IFNG-AS1 as a Candidate Diagnostic Biomarker. Int J Genomics. 2026 undefined undefined. doi: 10.1155/ijog/7231094. PMID: 42763619.

Ganji R, Salehi Z, Gholipour M, et al. Dysregulated expression of long non-coding RNAs IFNG-AS1 and GSTT1-AS1 in patients with multiple sclerosis. Neurol Sci. 2019;40(10):2145-2151.

Ghafouri-Fard S, Taheri M, Omrani MD. Downregulation of Cancer-Associated lncRNAs in Peripheral Blood of Multiple Sclerosis Patients. J Mol Neurosci. 2020;70(11):1858-1865.

Thompson AJ, Bar-Or A, Cohen JA, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.